Should You Buy Nivalis Therapeutics Inc (NVLS)?

Page 2 of 2

Consequently, some big names have jumped into Nivalis Therapeutics Inc (NASDAQ:NVLS) headfirst. OrbiMed Advisors, led by Samuel Isaly, created the most outsized position in Nivalis Therapeutics Inc (NASDAQ:NVLS). OrbiMed Advisors had $0.5 million invested in the company at the end of the quarter. Philip Hempleman’s Ardsley Partners also initiated a $0.1 million position during the quarter.

Let’s now review hedge fund activity in other stocks – not necessarily in the same industry as Nivalis Therapeutics Inc (NASDAQ:NVLS) but similarly valued. These stocks are Xerium Technologies, Inc. (NYSE:XRM), Corium International Inc (NASDAQ:CORI), Delta Apparel, Inc. (NYSEAMEX:DLA), and ArQule, Inc. (NASDAQ:ARQL). This group of stocks’ market values are similar to NVLS’s market value.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
XRM 12 17640 1
CORI 3 19184 -1
DLA 2 8336 -1
ARQL 8 35313 1

As you can see these stocks had an average of 6 hedge funds with bullish positions and the average amount invested in these stocks was $20 million. That figure was $63 million in NVLS’s case. Xerium Technologies, Inc. (NYSE:XRM) is the most popular stock in this table. On the other hand Delta Apparel, Inc. (NYSEAMEX:DLA) is the least popular one with only 2 bullish hedge fund positions. Compared to these stocks Nivalis Therapeutics Inc (NASDAQ:NVLS) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Disclosure: None

Page 2 of 2